[{"id":"101983fb-7628-475a-80b5-d17bf993dca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02988817","created_at":"2021-12-09T22:53:42.151Z","updated_at":"2024-07-02T16:35:41.314Z","phase":"Phase 1/2","brief_title":"Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors","source_id_and_acronym":"NCT02988817","lead_sponsor":"Genmab","biomarkers":" AXL • MUC16","pipe":" | ","alterations":" AXL expression • AXL positive","tags":["AXL • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL expression • AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enapotamab vedotin (HuMax-AXL-ADC)"],"overall_status":"Completed","enrollment":" Enrollment 306","initiation":"Initiation: 11/23/2016","start_date":" 11/23/2016","primary_txt":" Primary completion: 11/12/2021","primary_completion_date":" 11/12/2021","study_txt":" Completion: 11/12/2021","study_completion_date":" 11/12/2021","last_update_posted":"2023-08-01"},{"id":"3fbb4956-9efb-48d1-85dd-3eccb081995e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05128786","created_at":"2021-11-22T14:53:25.733Z","updated_at":"2024-07-02T16:35:50.288Z","phase":"Phase 1","brief_title":"CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas","source_id_and_acronym":"NCT05128786","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" AXL","pipe":" | ","alterations":" AXL positive","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CCT301-038"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2023-04-18"}]